Company intelligence / Profile preview

PercuSense

Huntington Beach, California, United States

Ownership: Private
Development stage: Other

Overview

PercuSense completed first-in-human feasibility testing on its novel continuous multi-analyte biosensor platform in August 2023[4]. Groundbreaking first-in-human results from the multi-analyte glucose and lactate sensor were published in August 2024[4]. The company is developing the Atlas Health system for metabolic monitoring and a CGKM (continuous glucose and ketone monitor) for diabetes management[3][6].

Therapeutic areas: EndocrinologyOtherMetabolic Disorders
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

University of Melbourne (funded by Leona M. and Harry B. Helmsley Charitable Trust for CGKM development)[2]

Beyond the preview

Go deeper on PercuSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PercuSense.

Explore the full profile